FDA Relaxes Oversight of Blood Pressure Wearables, Raising Clinical Accuracy Concerns

The FDA has relaxed regulatory oversight of wellness wearable devices, allowing blood pressure monitoring technology to enter the market without clinical validation. This policy shift enables consumer devices with unverified accuracy to proliferate, potentially affecting remote patient monitoring programs that Medicaid managed care organizations use for hypertension management and chronic disease monitoring. MCOs relying on wearable data for care management and quality metrics should assess whether their contracted devices meet clinical accuracy standards, particularly for programs serving members with cardiovascular conditions.

Managed Care